Helius Medical Technologies

HSM-T

Analysis and Opinions about HSM-T

Signal
Opinion
Expert
TOP PICK
TOP PICK
January 11, 2019
He has been investing in this for almost three years now. They received Health Canada approval for a new brain stimulation medical device last fall. They are awaiting FDA approval in the US. It magnifies the result of physio-therapy for the brain and the technology is safe. It is a billion dollar business if it receives that approval. Higher risk, but could have amazing returns. It has no correlation to current market uncertainty -- its result is solely based on government approval. Yield 0%. (Analysts’ price target is $18.86)
Show full opinionHide full opinion
He has been investing in this for almost three years now. They received Health Canada approval for a new brain stimulation medical device last fall. They are awaiting FDA approval in the US. It magnifies the result of physio-therapy for the brain and the technology is safe. It is a billion dollar business if it receives that approval. Higher risk, but could have amazing returns. It has no correlation to current market uncertainty -- its result is solely based on government approval. Yield 0%. (Analysts’ price target is $18.86)
PAST TOP PICK
PAST TOP PICK
May 8, 2018

(A Top Pick May 30, 2017. Up 8%). These are exciting times for the company. They are going through FDA approval. He believes that it will be approved because the device has low risk and addresses an unmet need. The stock was recently $25 a share, and he thinks it will rise to $50 if everything works out as planned.

Show full opinionHide full opinion

(A Top Pick May 30, 2017. Up 8%). These are exciting times for the company. They are going through FDA approval. He believes that it will be approved because the device has low risk and addresses an unmet need. The stock was recently $25 a share, and he thinks it will rise to $50 if everything works out as planned.

DON'T BUY
DON'T BUY
January 8, 2018

They have an incredible market cap for a company that doesn’t actually do anything yet. It seems the last announcement they had didn’t have the testing being successful. Be careful here. It is being promoted. It is interesting but he would stay clear of it.

Show full opinionHide full opinion

They have an incredible market cap for a company that doesn’t actually do anything yet. It seems the last announcement they had didn’t have the testing being successful. Be careful here. It is being promoted. It is interesting but he would stay clear of it.

WATCH
WATCH
November 16, 2017

They put out some numbers from their trial that the one analyst covering it who called the trial a failure. The company doesn't agree, and there was a lot of confusion. The group getting the actual treatment showed a 75% result but the sham group had a 60% result. As It's an electrical current, they had to give the control group some electrical current otherwise they would know. The company felt that was great news as it showed that the device worked even at a lower frequency. It enhances physiotherapy for people who have motor issuws. There is more data coming out and in a year we will know more.

Show full opinionHide full opinion

They put out some numbers from their trial that the one analyst covering it who called the trial a failure. The company doesn't agree, and there was a lot of confusion. The group getting the actual treatment showed a 75% result but the sham group had a 60% result. As It's an electrical current, they had to give the control group some electrical current otherwise they would know. The company felt that was great news as it showed that the device worked even at a lower frequency. It enhances physiotherapy for people who have motor issuws. There is more data coming out and in a year we will know more.

COMMENT
COMMENT
October 5, 2017

A medical device that helps brain injury, as well as the potential to help with other diseases. He started recommending this at about $1.25, and it doubled in about a year, and he added more to his holdings. At this point, he has his original money out, but still owns a lot. Feels it has a lot of potential. It looks like FDA approval is a given and the data is coming out in a couple of weeks.

Show full opinionHide full opinion

A medical device that helps brain injury, as well as the potential to help with other diseases. He started recommending this at about $1.25, and it doubled in about a year, and he added more to his holdings. At this point, he has his original money out, but still owns a lot. Feels it has a lot of potential. It looks like FDA approval is a given and the data is coming out in a couple of weeks.

SPECULATIVE BUY
SPECULATIVE BUY
August 21, 2017

They make a device that is being tested to treat traumatic brain injury including a lot of soldiers in the US. Results should be out in September. Data is what gets people excited. If it is good and early signs are good. Then they go into FDA approval and the stock multiplies in price. It is high risk, but he thinks you will see enthusiasm in September. He is confident they will get FDA approval. The military really needs this to happen for all their wounded soldiers.

Show full opinionHide full opinion

They make a device that is being tested to treat traumatic brain injury including a lot of soldiers in the US. Results should be out in September. Data is what gets people excited. If it is good and early signs are good. Then they go into FDA approval and the stock multiplies in price. It is high risk, but he thinks you will see enthusiasm in September. He is confident they will get FDA approval. The military really needs this to happen for all their wounded soldiers.

PAST TOP PICK
PAST TOP PICK
May 30, 2017

(A Top Pick April 27/16. Up 31%.) Still very bullish on this. Makes a medical device that can help with traumatic brain injuries, along with other things. They are close to sending in data to FDA on a traumatic brain injury study. Thinks the stock is going to start to move as we get closer to that date. It looks like this could be an “over-the-counter” product for consumers.

Show full opinionHide full opinion

(A Top Pick April 27/16. Up 31%.) Still very bullish on this. Makes a medical device that can help with traumatic brain injuries, along with other things. They are close to sending in data to FDA on a traumatic brain injury study. Thinks the stock is going to start to move as we get closer to that date. It looks like this could be an “over-the-counter” product for consumers.

TOP PICK
TOP PICK
May 30, 2017

He thinks there is going to be a run up, because often times in Biotech’s you get a run into the news, so he thinks it will do well as we get closer to the big announcements, regardless of what the outcome is. The downside has been mitigated by the fact that it could be a consumer business. (Analysts’ price target is $2.34.)

Show full opinionHide full opinion

He thinks there is going to be a run up, because often times in Biotech’s you get a run into the news, so he thinks it will do well as we get closer to the big announcements, regardless of what the outcome is. The downside has been mitigated by the fact that it could be a consumer business. (Analysts’ price target is $2.34.)

SPECULATIVE BUY
SPECULATIVE BUY
February 16, 2017

The odds for shareholders have improved. They are in FDA trials. They are speculative and make no money. He likens it to a lottery ticket or better, to a raffle ticket as the odds are better.

Show full opinionHide full opinion

The odds for shareholders have improved. They are in FDA trials. They are speculative and make no money. He likens it to a lottery ticket or better, to a raffle ticket as the odds are better.

SPECULATIVE BUY
SPECULATIVE BUY
December 2, 2016

A biotech company. Speculative because they don’t have any revenues yet. They are testing out a device called The Pons, which has been shown to improve a recovery rate in people that have traumatic brain injuries and illnesses like MS. In FDA trials right now. What makes it interesting is that it is in an unmet need.

Show full opinionHide full opinion

A biotech company. Speculative because they don’t have any revenues yet. They are testing out a device called The Pons, which has been shown to improve a recovery rate in people that have traumatic brain injuries and illnesses like MS. In FDA trials right now. What makes it interesting is that it is in an unmet need.

SPECULATIVE BUY
SPECULATIVE BUY
September 9, 2016

Has a device that seems to be able to help people recover from MS, brain damage, etc., in conjunction with physiotherapy. They are in FDA trials right now. The real question is efficacy. What is interesting is that it is aimed at what is called an unmet need, i.e., there is nothing out there to treat people with traumatic brain injury. Very speculative. If they fail, the stock will get crushed, but if they succeed, the stock will go up a lot.

Show full opinionHide full opinion

Has a device that seems to be able to help people recover from MS, brain damage, etc., in conjunction with physiotherapy. They are in FDA trials right now. The real question is efficacy. What is interesting is that it is aimed at what is called an unmet need, i.e., there is nothing out there to treat people with traumatic brain injury. Very speculative. If they fail, the stock will get crushed, but if they succeed, the stock will go up a lot.

TOP PICK
TOP PICK
April 27, 2016

Makes a medical device called the PONS, which appears to dramatically improve the results of therapy for people with brain injuries. They are in an FDA 3rd round right now. Results will probably be out in Q3. If results are positive, the stock will multiply, if not the stock is going to get crushed.

Show full opinionHide full opinion

Makes a medical device called the PONS, which appears to dramatically improve the results of therapy for people with brain injuries. They are in an FDA 3rd round right now. Results will probably be out in Q3. If results are positive, the stock will multiply, if not the stock is going to get crushed.

Showing 1 to 12 of 12 entries
  • «
  • 1
  • »

Helius Medical Technologies(HSM-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Helius Medical Technologies is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Helius Medical Technologies(HSM-T) Frequently Asked Questions

What is Helius Medical Technologies stock symbol?

Helius Medical Technologies is a Canadian stock, trading under the symbol HSM-T on the Toronto Stock Exchange (HSM-CT). It is usually referred to as TSX:HSM or HSM-T

Is Helius Medical Technologies a buy or a sell?

In the last year, there was no coverage of Helius Medical Technologies published on Stockchase.

Is Helius Medical Technologies a good investment or a top pick?

Helius Medical Technologies was recommended as a Top Pick by Fabrice Taylor on 2019-01-11. Read the latest stock experts ratings for Helius Medical Technologies.

Why is Helius Medical Technologies stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Helius Medical Technologies worth watching?

0 stock analyst on Stockchase covered Helius Medical Technologies In the last year. It is a trending stock that is worth watching.

What is Helius Medical Technologies stock price?

On 2020-02-27, Helius Medical Technologies (HSM-T) stock closed at a price of $1.11.